A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Exclusion Criteria

• •If human immunodeficiency virus (HIV) positive, must have well controlled HIV on antiretroviral therapy (ART)
• •Has diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements
• •Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea)
• •Has uncontrolled, significant cardiovascular disease or cerebrovascular disease
• •Has a gastrointestinal disorder affecting absorption
• •Is HIV positive and has a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
• •Has received prior systemic anticancer therapy for their advanced or metastatic NSCLC
• •Has known additional malignancy that is progressing or has required active treatment within the past 3 years
• •Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
• •Has active autoimmune disease that has required systemic treatment in the past 2 years
• •History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
• •Has active infection requiring systemic therapy except those specified by protocol
• •Has history of stem cell/solid organ transplant
• •Has not adequately recovered from major surgery or has ongoing surgical complications